Streetbeat News

Stock Prices

BSLK

GAMC

Bolt Threads has completed its business combination with Golden Arrow Merger Corp and will begin trading on Nasdaq under the new symbol 'BSLK' on August 14, 2024. This transaction aims to accelerate Bolt Threads' biomaterials platform, focusing on sustainable materials in the consumer goods industry.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:04 pm

TKNO

Alpha Teknova (NASDAQ:TKNO) reported Q2 2024 GAAP EPS of $(0.13), beating the $(0.16) estimate. Sales were $9.614M, surpassing the $9.463M estimate but down 16.60% from last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:04 pm

ATYR

aTyr Pharma (NASDAQ:ATYR) reported a Q2 EPS loss of $(0.23), beating the analyst consensus estimate of $(0.25) by 8%. This represents a 4.55% increase in losses compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:02 pm

SLRN

Acelyrin (NASDAQ:SLRN) reported a Q2 2024 GAAP EPS of $(0.86), missing the analyst consensus estimate of $(0.69) by 24.64%. This represents a 115% increase in losses compared to $(0.40) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:02 pm

TRGP

Targa Resources (NYSE:TRGP) has significantly outperformed the market over the past 5 years, delivering an average annual return of 31.04%. A $100 investment in TRGP 5 years ago would be worth $400.88 today. The company's current market capitalization is $30.14 billion.

Portfolio Pulse from Benzinga Insights

August 13, 2024 | 8:02 pm

NEE

NextEra Energy (NYSE:NEE) has outperformed the market over the past 20 years, producing an average annual return of 11.73%. A $1000 investment in NEE 20 years ago would be worth $9,123.74 today. The article highlights the impact of compounded returns on long-term investments.

Portfolio Pulse from Benzinga Insights

August 13, 2024 | 8:01 pm

CAE

CAE (NYSE:CAE) reported Q1 2025 adjusted EPS of $0.21, beating the estimate of $0.20. Sales were $1.07 billion, surpassing the $1.06 billion estimate and marking a 36.64% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:01 pm

SLRN

ACELYRIN announced that its Phase 3 trial for Izokibep met its primary endpoint, indicating positive results for the treatment. This is a significant milestone for the company.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:01 pm

SMCI

Super Micro Computer, Inc. (NASDAQ:SMCI) shares surged by 5.09% following the release of softer-than-expected Producer Price Index (PPI) figures for July 2024. The PPI increased by just 0.1% month-over-month and 2.2% annually, both below forecasts. This data suggests easing inflationary pressures, increasing the likelihood of Federal Reserve rate cuts, which could benefit tech companies by reducing borrowing costs and encouraging investment.

Portfolio Pulse from Vaishali Prayag

August 13, 2024 | 8:00 pm

LXRX

Analysts have provided mixed ratings for Lexicon Pharmaceuticals (NASDAQ:LXRX) over the past quarter, with all six analysts maintaining a bullish stance. The average 12-month price target remains at $10.00. Key financial indicators show strong revenue growth but challenges in profitability and asset returns.

Portfolio Pulse from Benzinga Insights

August 13, 2024 | 8:00 pm